163 related articles for article (PubMed ID: 27412562)
1. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.
Lu YS; Chen TW; Lin CH; Yeh DC; Tseng LM; Wu PF; Rau KM; Chen BB; Chao TC; Huang SM; Huang CS; Shih TT; Cheng AL;
Clin Cancer Res; 2015 Apr; 21(8):1851-8. PubMed ID: 25700303
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
Nakatsukasa K; Ouchi Y; Sakaguchi K; Goto M; Konishi E; Taguchi T
Anticancer Res; 2018 Sep; 38(9):5459-5463. PubMed ID: 30194203
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis.
Chen IC; Lin CH; Jan IS; Cheng AL; Lu YS
J Formos Med Assoc; 2016 Apr; 115(4):243-8. PubMed ID: 25890495
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.
Wu PF; Lin CH; Kuo CH; Chen WW; Yeh DC; Liao HW; Huang SM; Cheng AL; Lu YS
BMC Cancer; 2015 Apr; 15():299. PubMed ID: 25928457
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
Leone JP; Emblem KE; Weitz M; Gelman RS; Schneider BP; Freedman RA; Younger J; Pinho MC; Sorensen AG; Gerstner ER; Harris G; Krop IE; Morganstern D; Sohl J; Hu J; Kasparian E; Winer EP; Lin NU
Breast Cancer Res; 2020 Nov; 22(1):131. PubMed ID: 33256829
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
[TBL] [Abstract][Full Text] [Related]
10. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
[TBL] [Abstract][Full Text] [Related]
11. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
12. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
[TBL] [Abstract][Full Text] [Related]
13. Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.
Chen BB; Lu YS; Yu CW; Lin CH; Chen TW; Wei SY; Cheng AL; Shih TT
Eur Radiol; 2018 Nov; 28(11):4860-4870. PubMed ID: 29770848
[TBL] [Abstract][Full Text] [Related]
14. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
15. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
16. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
Chen TW; Dai MS; Tseng LM; Chen SC; Chao TY; Chao TC; Chang YC; Chiu CF; Liu CT; Lin CH; Liu CY; Chen YF; Chang DY; Yu JC; Rau KM; Hsieh YY; Shen SC; Huang SM; Cheng AL; Lu YS
JAMA Oncol; 2024 Mar; 10(3):325-334. PubMed ID: 38127335
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.
Chen TW; Jan IS; Chang DY; Lin CH; Chen IC; Chen HM; Cheng AL; Lu YS
J Neurooncol; 2020 May; 148(1):165-172. PubMed ID: 32346837
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
